CClinicalTrials.gg
Status unknownNCT03460041Updated Mar 9, 2018

Caudal Dexmetedomedine Versus Magnesium in Orthopedic Pediatric Surgeries

A Phase 4 interventional study of Magnesium Sulfate and Dexmetedomedine in Pain in Pediatric Patients, sponsored by Hagar hassanein refaee. Status unknown at 1 site in Egypt. Open to participants aged 1 Year to 7 Years. Per ClinicalTrials.gov, last updated 2018-03-09.

Sponsored by Hagar hassanein refaee · Phase 4, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
1 Year to 7 Years
Sex
All
01

Study summary

This study will be performed in Abo Elreesh Pediatric Hospital / Cairo University after obtaining approval by the University Ethics Committee, and a written informed consent from the parents or guardians.

Thirty six patients will be randomly assigned using an online randomization program (http://www.randomizer.org) and the sealed envelope method into three groups: Group D (n=12): Dexmetedomidine group. 0.5 ml of dexmetedomidine (2 μg/kg) added to bupivacaine, Group M (n=12) : Magnesium group.0.5 ml of magnesium sulphate (50 mg) added to bupivacaine, Group C (n=12) :Control group.bupivacaine 0.25% diluted in normal saline with total volume of 1 ml/kg.

Read the detailed description

History regarding previous anesthesia, surgery, any significant medical illness, medications and allergy will be taken for all children who will be enrolled in the study. Complete physical examination and airway assessment will be done. Hemoglobin percentage, blood sugar and coagulation profile will be investigated preoperatively Sedation will be done by giving midazolam (0.2 mg/kg IM).On arrival to the operating room all patients will be monitored by 5 leads electrocardiography (ECG), automated non-invasive blood pressure monitoring (NIBP), and pulse oximetery.

Inhalational induction of anesthesia will be achieved by 8% sevoflurane in 100% oxygen and an appropriate-sized cannula will be inserted. Endotracheal intubation will be performed after which sevoflurane concentration will be reduced to 3%. After hemodynamic stabilization, caudal block will be performed by using beveled needle 18-23 G in the lateral decubitus position by using the loss of resistance technique. The study solutions will be injected caudally slowly with repetitive intermittent aspiration by an anesthesiologist blinded to the test drugs. The inhaled concentration of sevoflurane will be adjusted to achieve hemodynamic changes less than 30% of the preoperative values

Recorded Parameters for the study:

Intraoperative hemodynamic: heart rates (beats/minutes), mean arterial blood pressure (mmHg) after stabilization, before skin incision and every 15 minutes till the end of surgery.

Sedation score: Sedation will be monitored after PACU arrival using Ramsay score with its 0-6 score range.

Pain score (FLACC score) with its 0-10 score range, each patient pain intensity will be assessed at the end of surgery and 12 hours postoperatively.

Time of rescue analgesia (from the time of caudal injection to the time at which FLACC score 4 or more) will be recorded.

Complication secondary to test drugs in the form of toxicity like postoperative nausea and vomiting, respiratory depression, hematoma, bradycardia (HR \<80 BPM) and hypotension (SBP \<70 mmhg+ age in years * 2) and complication secondary to caudal block; infection, hematoma and pain at the site of injection will be recorded.

Total doses of rescue drugs will be calculated for each group.

02

Conditions studied

  • Pain in Pediatric Patients
03

Who can participate

Ages eligible
1 Year to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age between 1 - 7 years old.
  • American Society of Anesthesiologist (ASA) physical status class I- II.
  • Patients scheduled for infra-umbilical orthopedic surgeries.

Exclusion criteria

Exclusion Criteria:

  • Patients with known allergy to the study drugs
  • Suspected coagulopathy.
  • Infection at the site of caudal block.
  • History of developmental delay or neuromuscular disorders.
  • Skeletal deformities.
  • Patients on magnesium therapy
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Placebo comparator
    Control

    Drug: Bupivacaine

  • Active comparator
    Magnesium

    Drug: Magnesium Sulfate

  • Active comparator
    Dexmetedomedine

    Drug: Dexmetedomedine

Interventions

  • DrugMagnesium Sulfate

    caudal magnesium sulphate added to bupivacaine for pain management

  • DrugDexmetedomedine

    Caudal dexmetedomedine added to bupivacaine for pain management

  • DrugBupivacaine

    Caudal bupivacaine for pain management

05

What researchers measure

Primary outcomes

  1. Postoperative pain

    Comparing duration of analgesia between caudal magnesium and caudal dexmetedomedine using flacc score

    Time frame: 12 hours

06

Study locations

1 of 1 sites recruiting
  • Cairo University faculty
    Cairo, Egypt
    • Cairo University · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03460041
Lead sponsor
Hagar hassanein refaee
Collaborators
Cairo University
Responsible party
Hagar hassanein refaee (Assistant lecturer, Cairo University) — Sponsor-investigator
First posted
Mar 9, 2018
Start date
Dec 1, 2017
Primary completion
Mar 15, 2018 (estimated)
Completion
Mar 15, 2018 (estimated)
Last update
Mar 9, 2018

Study contacts

Hagar Hassanein Refaee, Assistant lecturer
Contact
bibo_gogo12@yahoo.Com
01063949855
Mai Ahmed Aly, Lecturer
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion